ArticleFrontiers in immunology2026

Trajectory-based profiling of 52-week secukinumab response reveals baseline clinical and transcriptomic differences in plaque psoriasis.

Xiuxiu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.